Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546259 | 1.00 | CASP1 (0.38) | CASP1ALDH1A1PKMHPGDPDPK1 | |
| SCHEMBL5983208 | 0.83 | CASP1 (0.39) | CASP1DHFR | |
| SCHEMBL10697416 | 0.83 | KCNH2 (0.50) | ALDH1A1PKMHPGDKCNH2GPR84 | |
| SCHEMBL28413083 | 0.83 | KCNH2 (0.50) | ALDH1A1PKMHPGDKCNH2GPR84 | |
| SCHEMBL28300118 | 0.83 | KCNH2 (0.50) | ALDH1A1PKMHPGDKCNH2GPR84 | |
| SCHEMBL9817100 | 0.83 | KCNH2 (0.50) | ALDH1A1PKMHPGDKCNH2GPR84 | |
| SCHEMBL9133514 | 0.83 | KCNH2 (0.50) | ALDH1A1PKMHPGDKCNH2GPR84 | |
| SCHEMBL730079 | 0.83 | KCNH2 (0.50) | ALDH1A1PKMHPGDKCNH2GPR84 | |
| SCHEMBL4445935 | 0.83 | KCNH2 (0.50) | ALDH1A1PKMHPGDKCNH2GPR84 | |
| SCHEMBL27700043 | 0.83 | KCNH2 (0.50) | ALDH1A1PKMHPGDKCNH2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051293-B2 | Process for preparing episulfide compounds | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20140107350-A1 | Process for Preparing Episulfide Compounds | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107350-A1 | Process for Preparing Episulfide Compounds | TST, EPHX2, STS | CASP1 4390/4885ALDH1A1 405/4885PKM 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.